White Paper - ProImmune - Mastering Immunity _ MHC pentamers, CD1d tetramers, custom peptide synthesis, immunoassays, T cell epitope discovery, HLA tissue typing, cellular analysis, ligand binding assays, immune response

White Paper
Managing Immunogenicity Risk Through Assay-based Rational Drug Design and Selection

How can immunogenicity be managed effectively?
Can drugs be improved through better rational design methods?
And what can we learn from measuring T cell responses at the preclinical stage?

Download to find out more…

White Paper
Managing Immunogenicity Risk Through Assay-based Rational Drug Design and Selection

We would like to hear your point of view on the challenges of managing immunogenicity of biotherapeutics.Send us your feedback, or contact us for a discussion about managing immunogenicity risk in your drug development program.

Join the ‘Mastering Immunogenicity’ LinkedIn Group for topical discussions and updates:

Other resources for learning more about immunogenicity and ProImmune’s services:

ProImmune’s REVEAL® Immunogenicity System

Mastering Immunogenicity Conference

Conference Videos

Conference Presentations

Conference Knowledge Base: references and downloads

Webcast (November 2011): Mastering Immunogenicity – tools and technologies

Managing Biopharmaceutical Immunogenicity Risk (article in Drug Discovery & development)

White Paper Managing Immunogenicity Risk Through Assay-based Rational Drug Design and Selection

How can immunogenicity be managed effectively?

Can drugs be improved through better rational design methods?

And what can we learn from measuring T cell responses at the preclinical stage?

White Paper
Managing Immunogenicity Risk Through Assay-based Rational Drug Design and Selection